Medical technology and hospital supply - the rise of franchise value
This article was originally published in Clinica
1998 proved to be a good year for the US medical technology/ hospital supply industry. As of November 30, the group index (which is mainly large capitalisation in focus) advanced by over 29.5%, outperforming the market. Glenn Reicin of investment firm Morgan Stanley assesses future developments.
You may also be interested in...
Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
Resilience has raised $800m to develop new technologies to manufacture complex drugs including vaccines, cell therapies and gene therapies.